Drug Database
SA

saxagliptin (Bessin)

✓ Approved

Sino Biopharmaceutical Co., Ltd · DPP4 · Small Molecule

What is saxagliptin?

saxagliptin is a small molecule developed by Sino Biopharmaceutical Co., Ltd. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesBessin
CompanySino Biopharmaceutical Co., Ltd
Drug ClassSmall Molecule
Molecular TargetDPP4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sino Biopharmaceutical Co., Ltd

Mechanism of Action

Molecular Targets

saxagliptin acts on 1 molecular target:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

saxagliptin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedBMC pharmacology & toxicology2026-10-15

Development and validation of a GC-MS method for the determination of ethylene glycol and diethylene glycol in pharmaceutical syrups.

Amil Muhammad Amirul MA, Mohamad Adzib Muhammad Shahariz MS, Bujang Nur Baizura NB, Gan Kok Zheng KZ et al.

Contamination of pharmaceutical syrups with ethylene glycol (EG) and diethylene glycol (DEG) has led to serious poisoning incidents worldwide, highlighting the necessity for strong regulations and reliable testing methods. A gas chromatography-mass spectrometry (GC-MS) method was developed and validated in accordance with ICH Q2(R2) guidelines. The method was developed for pharmaceutical syrup matrices and validated using multiple commercially available products, supporting its applicability for routine regulatory surveillance. It exhibited excellent linearity, with r² of 0.9991 for EG and 0.9963 for DEG. The detection (LOD) and quantification (LOQ) limits were 0.02% v/v and 0.06% v/v, respectively, below the regulatory limit of 0.10% set by the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Accuracy ranged from 94.2% to 108.4%, and the %RSD for intermediate precision was 1.4% for EG and 2.5% for DEG, confirming the method's reproducibility. When the validated method was applied to 51 pharmaceutical syrup samples available in the Malaysian market as part of post-market surveillance, 13 samples were detected to have EG. Of these, 11 samples had EG concentrations between the LOD and the LOQ, while two samples (PS-13 and PS-26) had measurable levels at 0.09% v/v. DEG was not detected in any sample. Therefore, this study emphasises the importance of regulatory surveillance, supported by validated analytical testing, to ensure the quality and safety of pharmaceutical syrups. Strengthening local surveillance mechanisms will further strengthen NPRA's regulatory capacity and safeguard public health.

PMID 42875787
Read full article →
PubMedFrontiers in medicine2026-10-15

Case Report: Analysis of antimicrobial therapy and pharmaceutical care of mixed Aspergillus and Mycobacterium tuberculosis infection following renal transplantation: a case study.

Zhang Jiao J, Zhao Yue Y, Peng Yang Y, Zheng Xin X

Invasive infection is a significant complication following renal transplantation. Due to long-term immunosuppressive therapy, renal transplant recipients are at high risk for fungal infections and tuberculosis, which are also major causes of mortality in this population. Triazole drugs, as first-line agents for invasive fungal infections, can cause fluctuations in the blood levels of immunosuppressants due to drug-drug interactions. Furthermore, the concomitant use of antituberculosis drugs further complicates the balance between maintaining immunosuppression and anti-infective therapy, often presenting a challenge to clinical decision-making. This article discusses the role of the clinical pharmacist in the treatment of a renal transplant recipient who developed concurrent pulmonary tuberculosis and aspergillus infection. By recommending initial regimens, adjusting doses during outpatient follow-ups, and assessing adverse drug reactions, the clinical pharmacist provided systematic pharmaceutical services. This collaboration assisted physicians in developing a personalized treatment plan, ultimately achieving favorable therapeutic outcomes for the patient.

PMID 42876480
Read full article →
PubMedDrugs2026-10-15

Ciprocopan: First Approval.

Fung Simon S

Ciprocopan (®) is a small molecule inhibitor of complement factor B, which is a key component of the alternative complement pathway. It is being developed by Haisco Pharmaceutical Group for the treatment of complement-mediated disorders. In July 2026, ciprocopan received its first approval for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have not previously received treatment with a complement inhibitor therapy in China. This article summarizes the milestones in the development of ciprocopan leading to this first approval.

PMID 42875656
Read full article →
PubMedNature communications2026-10-15

Difunctionalization of unsaturated hydrocarbons via EDA complexes to access pentafluorosulfanyl thioethers.

Zhang Xiaofeng X, Jiang Yuanyang Y, Yang Hui-Yi HY, Ma Yifan Y et al.

Recently, the pentafluorosulfanyl (SF5) group has attracted considerable interest from medicinal chemists owing to its capacity to significantly enhance the pharmaceutical properties of small-molecule drug candidates. However, a general method for three-component pentafluorosulfanylation of electron-deficient alkenes remains elusive. Herein, we present an electron donor-acceptor (EDA) complex photoactivation strategy for the thiopentafluorosulfanylation of unsaturated hydrocarbons, including electron-deficient alkenes, alkynes, 1,6-enynes, and even acetylene gas. The utility of this approach is demonstrated through the synthesis of a diverse array of pentafluorosulfanyl thioethers and the late-stage functionalization of complex molecules, including pharmaceuticals, natural products, and amino acid derivatives. This work establishes a framework for designing atom-economical difunctionalization reactions that employ green LEDs under mild conditions. Moreover, mechanistic studies support an EDA complex-mediated pathway and identify ArSCl as a key intermediate formed upon generation of the thiyl radical.

PMID 42875439
Read full article →
PubMedNature communications2026-10-15

On-demand design of controlled-release systems using an expert-mimic AI framework.

Qin Ying Y, Zhou Rushuang R, Ming Yali Y, Li Bohao B et al.

Navigating a vast formulation-preparation design space that is highly sensitive to perturbations makes trial-and-error approaches inefficient and costly for diverse clinical needs. Here, we introduce an expert-mimic AI framework called E-MAF that integrates a process-aware surrogate with an optimized genetic algorithm to emulate coarse-to-fine reasoning, autonomously generating lab-ready designs tailored to desired release profiles. We show that E-MAF delivers on-demand release and shortens design cycles from 6-12 months to approximately 1 hour. We demonstrate that in vitro release, in vivo pharmacokinetics and therapeutic effects match or surpass commercial benchmarks across 7 active pharmaceutical ingredients. We show that E-MAF also enables release profiles that are hard to achieve by conventional approaches, exemplified by ≤2% risperidone burst within 1 h and near-zero-order release over ~28 days in vivo. These results demonstrate E-MAF's potential to accelerate polymeric controlled-release system development and drug-delivery industrialization.

PMID 42875418
Read full article →
PubMedThe European journal of health economics : HEPAC : health economics in prevention and care2026-10-15

Age-specific COVID-19 case dynamics during school closure periods: Evidence from 12 european countries.

Dupré Damien D, Morgenroth Edgar E

School closures were among the most widely adopted non-pharmaceutical interventions against COVID-19, yet evidence on their association with infection dynamics remains uncertain given their substantial economic and educational costs. This observational study describes age-specific COVID-19 case dynamics during school closure periods across 12 European countries using Generalised Additive Models with zero-crossing derivative analysis and Transfer Entropy. Case dynamics were heterogeneous and non-monotonic across age groups: case counts declined early but rose again within the window among the youngest cohorts (0-4 and 5-9 years). By contrast, the 10-14 group rose steadily with no turning point, and older adolescents and young adults (15-19 and 20-24 years) rose early and then declined. Transfer Entropy analysis, with Benjamini-Hochberg correction, revealed asymmetric directional relationship between age cohorts that varied across national contexts. These patterns indicate that case trajectories during closure periods were not uniform across youth age groups, with no age group showing a sustained, uninterrupted decline. Interpreted cautiously, they raise questions about the cost-benefit balance of blanket closure policies when weighed against their documented economic, educational, and distributional costs, and motivate more targeted, age-sensitive quasi-experimental evaluation for future pandemic preparedness.

PMID 42875713
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about saxagliptin